Cardiex Ltd represents values of innovation, excellence, and dedication in the field of cardiovascular health. Committed to advancing the understanding and treatment of heart-related conditions, Cardiex aims to improve patient outcomes by leveraging cutting-edge technology. With a strong emphasis on research and development, the company strives to provide healthcare professionals and patients with advanced diagnostic technology and monitoring solutions. By continually pushing the boundaries of cardiovascular care, Cardiex is dedicated to improving the lives of individuals affected by heart diseases. With a focus on innovation and a commitment to excellence, Cardiex Ltd aims to make a profound impact in the cardiovascular healthcare industry.

Cardiex Ltd is primarily present in several countries and regions around the world. The company has a global presence, with its main focus on markets in North America, Europe, Asia-Pacific, and Latin America. Cardiex Ltd operates across various countries, including the United States, Canada, United Kingdom, Germany, France, China, Japan, Australia, Brazil, and many others. With its widespread presence, Cardiex Ltd is able to serve a diverse customer base and cater to the needs of people from different regions.

Cardiex Ltd has achieved several significant milestones since its establishment. The company successfully developed and commercialized the wearable health monitoring device called Healthstats, which provides accurate cardiovascular data to individuals. In addition, Cardiex partnered with leading healthcare organizations to conduct clinical trials and validate the effectiveness of their technology. The company also expanded its global presence by establishing distribution agreements in various countries, allowing wider access to its innovative products. Furthermore, Cardiex secured multiple patents for its technology, reinforcing its position as a key player in the digital healthcare sector. These milestones demonstrate Cardiex Ltd's commitment to revolutionizing cardiovascular monitoring and improving the lives of individuals worldwide.

Cardiex Ltd is a leading healthcare technology company specializing in the development of digital solutions for cardiovascular health management. Founded in [year], Cardiex has emerged as a pioneer in the field by integrating innovative technologies with clinical research. The company's mission is to revolutionize the prevention, diagnosis, and treatment of cardiovascular conditions globally. With a strong focus on research and development, Cardiex has been able to develop cutting-edge products and services that facilitate personalized and remote cardiac monitoring, enabling healthcare providers to deliver better patient care. Cardiex Ltd continues to drive advancements in the field of cardiovascular health, making it a key player in the industry.

The main competitors of Cardiex Ltd in the market include companies such as ABC Medical Technologies, XYZ Healthcare Solutions, and DEF Cardio Devices. These companies also specialize in the development and provision of innovative medical technologies and solutions for cardiovascular health. However, Cardiex Ltd differentiates itself by leveraging cutting-edge technology and advanced algorithms to provide a unique range of non-invasive monitoring solutions. With its focus on precision and accuracy, Cardiex Ltd continues to stay ahead of its competitors, delivering exceptional value to its customers in the market.

Cardiex Ltd is primarily active in the healthcare and medical technology industries.

The business model of Cardiex Ltd revolves around the development and commercialization of medical technologies focused on cardiovascular health monitoring. The company specializes in the design and manufacturing of innovative devices that assist in the diagnosis and management of various cardiovascular conditions. Cardiex Ltd aims to provide accurate and reliable data to healthcare professionals, enabling better patient outcomes and enhancing cardiovascular disease management. By leveraging advanced technologies and data analytics, Cardiex Ltd strives to create scalable solutions that empower individuals and healthcare providers with actionable insights for proactive heart health monitoring.

CardieX KGV ir -3,29.

CardieX KUV ir 2,30.

AlleAktien kvalitātes vērtējums CardieX ir 6/10.

CardieX apgrozījums ir 10,91 milj. AUD.

CardieX peļņa ir -7,64 milj. AUD.

Cardiex Ltd is a diversified company specialized in providing diagnostic and therapeutic devices for cardiovascular medicine. The company is divided into several business areas, including cardiology, telemedicine, and research and development. In the cardiology field, Cardiex Ltd offers a variety of products used by cardiologists and other medical professionals to diagnose and treat patients with heart diseases. This includes innovative monitors such as the Endo-PAT system, which measures the endothelial function of the vascular system, and the wristband device WatchBP Home A, which automatically measures blood pressure. Additionally, the company provides professional training and technical support to help customers implement and set up these systems. Cardiex Ltd also has a strong presence in the telemedicine field. The company offers a range of handheld products and services that enable medical professionals to conduct remote examinations and monitor patient data in real time. This includes the Endo-PAT system and the mobile EKG camera MCube, which allows users to record an EKG in real time and send it to the treating physician. The research and development arm of Cardiex Ltd focuses on creating new diagnostic and therapeutic devices for cardiology. The company works closely with leading medical research institutions and universities to develop and implement new technologies. Additionally, the company employs state-of-the-art techniques to improve the diagnostic and therapeutic devices and optimize their effectiveness and user experience. As a result, Cardiex Ltd is capable of offering tailor-made solutions to each customer. The company has a wide range of products and services to meet the individual needs of customers, whether they are a small medical practice team or a large medical research institution. Cardiex Ltd places great emphasis on meeting the requirements and high quality standards expected by its customers. Overall, the company has established a strong market position in the cardiology industry since its inception. Cardiex Ltd offers top-notch products that are well-received by the medical community while providing excellent customer care and technical support. Given the growing demand for cardiology in the global healthcare sector, the company is expected to continue expanding in the coming years. The company Cardiex Ltd specializes in providing diagnostic and therapeutic devices for cardiovascular medicine. It is divided into several business areas, including cardiology, telemedicine, and research and development. In the cardiology field, the company offers products used to diagnose and treat patients with heart conditions, such as the Endo-PAT system and the WatchBP Home A wristband device. It also provides training and technical support for implementing these systems. In telemedicine, Cardiex Ltd offers handheld products and services for remote examinations and real-time monitoring of patient data, including the Endo-PAT system and the MCube mobile EKG camera. The research and development arm focuses on creating new diagnostic and therapeutic devices, collaborating with institutions and universities. The company prioritizes meeting customer requirements and quality standards. Cardiex Ltd has gained a strong market position in the cardiology industry, offering top-quality products and excellent customer support. It is expected to further expand due to the increasing demand for cardiology in the healthcare sector.

CardieX izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt CardieX vai uzņēmums nedod dividendes.

CardieX ISIN ir AU0000015729.

CardieX WKN ir A2JN9Z.

CardieX simbols ir CDX.AX.

Pēdējo 12 mēnešu laikā CardieX maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos CardieX plāno maksāt dividendes 0 AUD apmērā.

CardieX pašreizējā dividendu rentabilitāte ir .

CardieX maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

CardieX pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

CardieX tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu CardieX apmērā 0 AUD, kas tika izmaksāta 8.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 8.11.2024..

Pēdējās dividendes izmaksa notika 8.11.2024..

Gadā 2023, CardieX izmaksāja 0 AUD dividendes.

CardieX dividendes tiek izmaksātas AUD.